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ABSTRACT We recently reported the synthesis and binding affinity of ligands for
the muscarinic acetylcholine receptor (mAChR) based on both the pyrrolidyl and pip-
eridyl benzilate scaffold. One of these, (R)-3-pyrrolidyl benzilate, was successfully
radiolabeled with [11C]methyl triflate and the resulting compound, (R)-N-[11C]methyl-
3-pyrrolidyl benzilate (3-[11C]NMPYB), was evaluated as a reversible, acetylcholine-
sensitive tracer for the mAChR (Ki of unlabeled 3-NMPYB is 0.72 nM). This compound
displayed high, receptor-mediated retention in regions of the mouse and rat brain known
to have high concentrations of mAChRs. Moreover, bolus studies in a pigtail monkey
showed that this compound had superior clearance from the brain when compared to
muscarinic radiotracers previously employed in human PET studies. Infusion studies in
the same monkey revealed that it was possible to achieve equilibrium of radiotracer
distribution for 3-[11C]NMPYB in both the striatum and cortex. Sensitivity to endoge-
nous acetylcholine levels was evaluated by injecting phenserine (5 mg/kg) into rats prior
to administration of 3-[11C]NMPYB in an equilibrium infusion protocol. This pretreat-
ment produced a modest, statistically significant decrease (9–11%) in the distribution
volume ratios for muscarinic receptor rich regions of the rat brain as compared to
controls. Synapse 45:31–37, 2002. © 2002 Wiley-Liss, Inc.
INTRODUCTION
The link between cholinergic dysfunction and Alzhei-
mer’s disease (AD) has now been well documented.
Changes of cholinergic function in AD include de-
creases in choline acetyltransferase (Aubert et al.,
1992; Kuhl et al., 1999; Mash et al., 1985; Nordberg
and Winblad, 1986; Perry et al., 1977), acetylcholines-
terase (Geula and Mesulam, 1994; Gsell et al., 1996;
Kuhl et al., 1999; Smith et al., 1988), high-affinity
choline uptake (Rodriguez-Puertas et al., 1994; Rylett
et al., 1983), and vesicular acetylcholine transporters
(Efange et al., 1997; Kuhl et al., 1996, 1999). Alter-
ations of numbers of the muscarinic acetylcholine re-
ceptor (mAChR), a G-protein coupled receptor involved
in the regulation of higher cognitive functions such as
memory and learning, have been described in some
studies (Caulfield et al., 1982; Fisher, 1999; Mash et
al., 1985; Nordberg and Winblad, 1986; Rodriguez-
Puertas et al., 1997) but these changes are more am-
biguous. Taken together, these changes in receptors,
enzymes, and transporters of the cholinergic system
have led to the hypothesis that enhancement of the
cholinergic function using mAChR agonists or acetyl-
cholinesterase (AChE) inhibitors can lead to ameliora-
tion of AD symptoms (review: Nordberg, 1999). While
numerous cholinergic drugs (AChE inhibitors, acetyl-
choline (ACh)-releasing agents, and cholinergic ago-
nists) have been developed for this purpose and several
are in routine clinical use, relatively little is known of
how these drugs affect muscarinic cholinergic receptor
occupancy by ACh.
The in vivo imaging of mAChR availability using
positron emission tomography (PET) or single photon
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emission computed tomography (SPECT) offers an at-
tractive opportunity for evaluating new or existing
pharmaceutical approaches to enhancing the cholin-
ergic system, provided a radiopharmaceutical with
demonstrated sensitivity to ACh levels was available.
Although numerous mAChR radiopharmaceuticals
have been developed (Dannals et al., 1988; Dewey et
al., 1990; Eckelman et al., 1985; Farde et al., 1996;
Frey et al., 1992; Koeppe et al., 1994; Mulholland et al.,
1995; Wilson et al., 1989, 1991), relatively few have
been designed for the express purpose of measuring
changes in endogenous ACh. Recently, Carson et al.
(1998) reported sensitivity of the agonist [18F]FP-TZTP
(3-(3-(3-fluoropropyl)thio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-
tetrahydro-1-methylpyridine) to physostigmine-induced
changes of ACh levels in monkey brain. Tsukada and
co-workers also reported recently the sensitivity of
two carbon-11 labeled piperidinyl benzilates, ()-3-N-
[11C]ethylpiperidinyl benzilate (3-EtPB) and ()-3-N-
[11C]propylpiperidinyl benzilate (3-PPB), to alterations
of ACh levels in conscious monkey brain following
pretreatment with the AChE inhibitor Aricept (Nish-
iyama et al., 2001). In rats, we have described the
sensitivity of 4-[18F]fluoroethylpiperidinyl benzilate (4-
[18F]FEPB) to changes of brain ACh levels following
pretreatment with the AChE inhibitor phenserine
(Skaddan et al., 2001). However, this last radiotracer
proved difficult to apply in an equilibrium infusion
protocol in monkeys due to metabolite issues (Skaddan
and Kilbourn, unpublished results).
We describe here the radiochemical synthesis of (R)-
N-[11C]methyl-3-pyrrolidyl benzilate (3-[11C]NMPYB),
and the evaluation of this new mAChR radioligand
in rodent and primate brain. The sensitivity of
3-[11C]NMPYB to endogenous ACh levels has been ex-
amined by pretreatment of rats with phenserine (5
mg/kg) and injection of 3-[11C]NMPYB in a bolus plus
infusion (equilibrium distribution) protocol. Finally,
this new radioligand has been evaluated as a reversible
radiotracer suitable for equilibrium infusion PET stud-
ies of mAChR availability in the primate brain.
MATERIALS AND METHODS
Synthesis of 3-[11C]NMPYB
No-carrier-added [11C]CO2 was prepared by proton
irradiation of a nitrogen gas target [14N(p,)11C] and
converted sequentially to [11C]methyl iodide and
[11C]methyl triflate (Jewett, 1992). 3-[11C]NMPYB was
produced by reacting [11C]methyl triflate with the des-
methyl precursor (1 mg) in 46 L of dimethylacet-
amide. After complete transfer of the [11C]methyl tri-
flate the reaction was diluted with 1 mL cyclohexane
and transferred to a neutral alumina column (4  110
mm). After washing the column with another 10 mL
cyclohexane, 3-[11C]NMPYB (2) was eluted with 1.5%
methanol/dichloromethane. The main portion of radio-
activity eluted at 10–13 mL. The collected portion was
evaporated under nitrogen and reformulated with 10%
ethanol/sterile water. For monkey studies, the final
formulation was passed through a 0.22 m pore size
filter.
Reversed-phase quality control HPLC analyses were
performed on a system consisting of a Beckman 110B
isocratic pump, a Hitachi L-4000H UV detector (220
nm), a Beckman Model 120 radioisotope detector, and a
Phenomenex C-8 (5 m, 4.6  250 mm) analytical
column. The mobile phase was 75% acetonitrile/0.05M
NH4OAc, with a flow rate of 1 mL/min.
To determine the lipophilicity of 2, an 80 Ci sample
was added to a premixed suspension of 2 mL octanol
and 2 mL phosphate-buffered saline (PBS, pH 7.4). The
resulting solution was vortexed for 2 min and centri-
fuged at 2,000 rpm for 5 min. An 800 L aliquot of the
octanol layer was transferred to a test tube containing
800 L PBS. The solution was mixed and centrifuged
as before. A 500 L aliquot of the octanol layer was
removed and extracted with 500 L PBS as before. The
radioactivity of each layer of the extractions was mea-
sured. Each octanol and water layer was weighed. The
partition coefficient was calculated as the ratio of
cpm/g of octanol to cpm/g of PBS per extraction. The
average log Po/w of the three extractions for 2 is re-
ported.
In vivo tissue distribution studies
The time-dependent regional brain distribution of
radioactivity was determined in female CD1 mice
(20–25 g, Charles River Laboratories) using a protocol
approved by the University of Michigan Committee on
Care and Use of Animals. Under diethyl ether anesthe-
sia, animals were injected with 211–349 Ci of 2 via
the tail vein, allowed to waken, and groups of animals
sacrificed at various times after injection. The brains
were quickly removed and dissected into regions of
interest. Blood samples and for certain time points
heart and bone (femur) samples were also obtained.
Tissue samples were counted for carbon-11 and then
weighed. Radioactivity retention for each region was
calculated as %ID/gram tissue. To ascertain whether
the uptake was receptor-mediated, sets (n  4) of
animals were administered scopolamine (5 mg/kg, i.p.)
or unlabeled 2 (5 mg/kg, i.p.) 15 min prior to adminis-
tration of the radiopharmaceutical.
Equilibrium regional brain distribution were deter-
mined in male CD rats (200–250 g, Charles River Lab-
oratories). Under sodium pentobarbitol anesthesia, an
infusion line was surgically inserted and secured in one
femoral vein. The rats were restrained (plastic tubes)
and allowed to waken. Radiotracer infusions were done
using a Harvard programmable infusion pump which
administered 2 (4.02  1.07 mCi) as a bolus of 1 mL
delivered over 1 min followed by a constant infusion of
the remaining 0.5 mL over a period of 79 min. At the
end of the infusion animals were sacrificed with sodium
32 M.B. SKADDAN ET AL.
pentobarbitol overdose and the brains were removed
and dissected into regions of interest (ROIs). Tissue
samples were counted for carbon-11 and then weighed.
Radioactivity retention for each region was calculated
as %ID/gram tissue.
Studies of the effects of pretreatment with
phenserine (5 mg/kg i.p., administered 30 min prior)
were done in rats using the bolus  infusion protocol.
Monkey PET imaging
The primate PET imaging studies were conducted in
a female pigtail monkey (Macaca nemistrina) weighing
8.3 kg. Imaging was done using TCC 4600A three-ring,
five-slice PET camera, modified with custom collima-
tion to provide an in-plane resolution of 7.5 mm
FWHM. The primate was anesthetized (15 mg/kg i.m.
ketamine and 2 mg/kg i.m. xylazine, repeated as nec-
essary) and intubated to prevent aspiration of salivary
secretions. An [15O]H2O scan was performed to verify
the position of the monkey brain within the scanner
field of view. The bolus study was initiated with an i.v.
injection of 26 mCi of 2. For the equilibrium infusion
studies (n  2) involving 2, 50% of the total activity
(total doses of 53.9, 50.0 mCi) was administered as a
bolus during the first minute using a Harvard pro-
grammable infusion pump and the remaining 50% was
infused at a constant rate over the next 89 min. For all
studies kinetic data were acquired using a 20 frame
acquisition sequence which lasted 90 min (five frames
of 1 min duration, 17 frames at 5 min/frame for the
remaining 85 min). A mathematical attenuation cor-
rection was applied in image reconstruction. ROIs were
drawn around the frontal/temporal cortex and around
each striatum and these regions applied to all images
in the sequence to generate tissue time–activity curves.
Rodent metabolite studies
In vivo metabolism studies were carried out in fe-
male CD1 mice (25–30 g, Charles River Laboratories).
Under diethyl ether anesthesia, animals were injected
with 2 (1.2 mCi/mouse) via the tail vein, allowed to
waken, and sacrificed at various times after injection
(one animal per time point). Whole mouse brain was
placed in a polystyrene tube containing 1 mL ethanol,
then homogenized. Blood (500 L) was also removed
and placed in a 1.5 mL Eppendorf tube containing 750
L ethanol, then shaken. The blood and brain tubes
were centrifuged at 3,500 rpm for 5 min and the super-
natant was spotted (3  5 L) onto glass silica TLC
plates (vide supra). The spots were dried by heating the
back of the plate with a heat gun for 15–20 sec. After
cooling, the plates were developed in a chamber con-
taining 5% methanol/dichloromethane. The chamber
was also saturated with NH3 by placing a vial inside
containing concentrated NH4OH. After the plates were
developed they were removed, air-dried, and radioac-
tivity was visualized using a Fuji phosphorimaging
system. ROIs corresponding to the authentic radio-
tracer, radioactive metabolite, and chromatographic
origin were drawn by hand on these images. An addi-
tional ROI was drawn in a blank area of the plate to
serve as a background correction and the optical den-
sity for each ROI was quantified. The fraction of au-
thentic radiotracer at each time point was calculated as
the optical density of the authentic tracer ROI divided
by the total signal in all regions and was converted to
a percentage.
Statistics
Statistical significance of drug pretreatments was
evaluated using an unpaired Student’s t-test. P 
0.05 was considered significant.
RESULTS
The radiochemical synthesis of 2 proceeded a via
alkylation of the nor-precursor with [11C]methyl tri-
flate, using dimethylacetamide as the solvent (Fig. 1).
The reaction is extremely rapid, reproducible, and re-
liable and the desired product can be purified by simply
passing the reaction contents through a short neutral
alumina column, thus eliminating the need for HPLC
purification. Typical results for a 25-min, 20-A irra-
diation target irradiation were 350 mCi of 2 in 96%
radiochemical purity. Overall synthesis times were
15–20 min from end-of-bombardment, but synthesis
times and yields were not optimized. Apparent specific
activities from HPLC analysis were on the order of
1,500–3,000 Ci/mmol, with only trace amounts (1
g/mL) of nor-precursor 1 present in the final solution.
The time-dependent in vivo tissue distribution of 2 in
mouse brain is summarized in Table I. Uptake in the
brain was highest in the striatum, cortex, and hip-
pocampus and lowest in the hindbrain, which corre-
sponds well to known regional brain concentrations of
mAChRs (Lee et al., 1995; Lin et al., 1986; Snyder et
al., 1975). Blocking doses of the mAChR antagonist
scopolamine at the 20-min timepoint resulted in signif-
icant decreases in striatal (84%) and cortical (75%)
radioactivity concentrations. Significant decreases (65–
75%) were observed when blocking studies were car-
ried out with unlabeled 2 (Ki  0.72 nM). These
Fig. 1. Synthesis of 3-[11C]NMPYB (2).
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findings demonstrate that uptake in the receptor-rich
regions of the brain was mAChR-mediated.
In the equilibrium infusion studies in rats a similar
pattern of distribution was evident (striatum  cor-
tex  hippocampus  hypothalamus, thalamus  cer-
ebellum), but smaller region/cerebellum ratios were
obtained (Fig. 1). This was not surprising, as we and
others have described significantly different tissue con-
centration ratios following bolus and equilibrium ra-
diotracer distributions (Kilbourn and Sherman, 1997).
These ratios obtained at equilibrium, which represent
distribution volume ratios and are directly propor-
tional to the binding potential of the tissues (DVR 	 BP
1), are a widely used and more accepted estimate of
specific binding than tissue ratios obtained at a single
time point following bolus radiotracer injection. Sensi-
tivity of the equilibrium specific binding measures to
changes in endogenous acetylcholine levels was studied
using pretreatment with phenserine (a potent AChE-
inhibitor [Grieg et al., 1995]) or saline 30 min prior to
infusion of 2. The dose of phenserine chosen (5 mg/kg)
significantly inhibits brain acetylcholinesterase (Kil-
bourn et al., 1999). Inhibition of AChE by phenserine
produced a statistically significant decrease in the dis-
tribution volume ratio for the striatum (9%, P 
0.03), cortex (11%, P  0.02), and hippocampus
(10%, P  0.01) following phenserine pretreatment
(Fig. 2). These decreases were due entirely to changes
in radioligand binding to these regions and not because
of increased uptake or retention in the cerebellum (the
reference region), as radioactivity concentrations in
that region of the brain remained unchanged through-
out all of the studies (controls, 0.17  0.01% injected
dose/g; phenserine, 0.17  0.05% injected dose/g).
The regional tissue time–activity curves (TAC) of 2
following a bolus injection into a monkey is shown in
Figure 3. The time–activity curves of cortical uptake
and clearance in monkey brain for the structurally
related muscarinic radiotracers 4-[11C]NMPB and
[18F]FEPB are shown for comparison. All of these ben-
zilate esters are moderately lipophilic and show high
early uptake into brain tissues. Clearance of 2 from the
cortex is more rapid than that of 4-[11C]NMPB but not
as fast as the fluorinated derivative. This agrees well
with the 10-fold lower muscarinic receptor binding af-
finity reported for unlabeled 3-NMPYB vs. 4-NMPB
(Skaddan et al., 2000). The kinetics of 2 compare more
favorably to [18F]FEPB, a compound we have shown to
be a reversible, ACh-sensitive muscarinic agent in rats
(Skaddan et al., 2001a).
The tissue radioactivity curves for 2 in monkey brain
following a bolus  infusion is presented in Figure 4.
With a bolus to infusion ratio of 50:50, the time–activ-
ity curves of the striatum and cortex reach a plateau by
50 min into the infusion. Thus, it is possible not only to
achieve equilibrium distributions of 2 in rodents, but in
monkey brain as well. Distribution volume ratios
(DVRs) in the monkey brain, calculated as ratios of
equilibrium concentrations in ROIs to cerebellum,
were 3.52  0.18 for the striatum and 2.70  0.10 for
the cortex for 50–90 min (average for nine consecutive
5-min PET scans of one study). Reversibility of the
TABLE I. Tissue distribution (%ID/gram) of 2 in female CD1 mice
Tissue
%ID/gram  SD, n  4




block 2b 60 min
Striatum 11.30  1.74 15.04  1.28 2.43  0.85 3.92  0.90 11.04  1.87
Cortex 11.41  1.51 12.91  0.81 3.20  0.92 4.61  0.87 8.72  0.46
Cerebellum 7.70  1.21 2.94  0.28 2.36  0.65 3.15  0.55 1.49  0.12
Hippocampus 11.79  1.64 12.53  1.10 3.25  0.93 4.36  0.75 9.03  0.46
Hypothalamus 11.91  1.36 7.78  1.68 2.34  0.70 3.40  0.71 3.99  0.50
Thalamus 10.89  1.46 7.62  1.26 2.30  0.69 2.88  0.42 3.20  0.23
Pons/medulla 9.10  1.04 5.52  0.61 2.37  0.66 3.19  0.57 2.27  0.08
Rest of brain 9.90  1.83 7.84  1.21 2.32  0.60 3.27  0.57 4.21  0.27
Heart 9.30  1.18 2.36  0.72 N/A N/A 1.78  0.09
Blood 1.57  0.11 1.58  0.03 1.55  0.19 1.76  0.07 1.60  0.12
Striatum/cereb. 1.49  0.18 5.16  0.62 1.01  0.18 1.23  0.15 7.42  1.27
Cortex/cereb. 1.49  0.13 4.42  0.35 1.35  0.08 1.46  0.03 5.87  0.22
an  8.
b5 mg/kg.
Fig. 2. Comparison of regional brain 3-[11C]NMPYB distribution
volume ratios between control and phenserine-treated male rats. Rats
were injected with either saline (n  8, controls) or phenserine (5
mg/kg: n  8) 30 min prior to beginning the injection of
3-[11C]NMPYB in a bolus plus infusion protocol for 80 min. Distribu-
tion volume ratios (DVRs) are ratios of concentrations of radioactivity
in ROIs relative to the cerebellum, presented as mean  SD. *P 
0.05 vs. controls.
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binding of 3-[11C]NMPYB could be clearly demon-
strated by following the rapid washout of radioactivity
from all brain regions following the end of the constant
infusion of the radiotracer (Fig. 4A). The rapid, revers-
ible kinetics of 3-[11C]NMPYB are a significant im-
provement over the previous carbon-11 labeled mAChR
radioligands we have previously introduced into clini-
cal PET imaging, namely [11C]scopolamine, [11C]tropa-
nyl benzilate, and 4-[11C]NMPB, none of which were
applicable to an equilibrium infusion protocol.
Limited metabolite studies of 2 in mice were per-
formed since the metabolic profile of this class of com-
pounds has already been extensively covered (Hüller et
al., 1988; Kiesewetter et al., 1997; Mulholland et al.,
1992; Nishiyama et al., 2001; Skaddan et al., 2001b;
Tsuda et al., 1991; Tsukada et al., 2001). As with most
of the amine benzilates, 2 is rapidly metabolized in
vivo, with 80% authentic (RF  0.74) remaining after
2 min, 35% after 20 min, and 13% after 40 min in whole
mouse blood. The major metabolites remained at the
baseline with the mobile phase used and therefore
would not be expected to cross the blood–brain barrier.
Indeed, after 20 min 97% of the TLC activity from
whole brain extracts was associated with authentic 2.
DISCUSSION
The advantage of infusing a radioligand to equilib-
rium over traditional bolus techniques is that it pro-
vides an excellent method of determining distribution
volume ratios (DVRs, the ratio of radioactivity in re-
gions of the brain with high concentrations of musca-
rinic receptors to regions with low or no concentration
of receptors), an in vivo estimate of specific binding
which is proportional to the numbers of available bind-
ing sites and which can be obtained independent of
changes in radiotracer metabolism or delivery (i.e.,
blood flow) (Carson et al., 1998). In contrast to many
previous radioligands we have evaluated as PET radio-
tracers for the mAChR, such as [11C]scopolamine,
[11C]tropanyl benzilate, and 4-[11C]N-methylpiperidi-
nyl benzilate (4-NMPB), the radioligand developed
here ([11C]NMPyB) is rapidly reversible and thus can
Fig. 3. A: Tissue time–activity curves in monkey brain for stria-
tum, cortex and cerebellum following bolus injection of
3-[11C]NMPYB. B: Comparison of cortical time–activity curves for
3-[11C]NMPYB with the structurally related radioligands
4-[11C]NMPB and 4-[18F]FEPB. Data has been normalized to account
for differences in injected doses.
Fig. 4. A: Time–activity curves of monkey cortex and striatum
following injection of 3-[11C]NMPYB using a bolus plus infusion pro-
tocol. The arrow indicates the time point at which radiotracer admin-
istration was stopped and radioactivity began washing out of brain
regions. B: Tissue time–activity curves for the time period 50–90 min,
demonstrating constant tissue concentrations of radioactivity during
the later stages of the constant infusion period of a bolus  infusion
protocol.
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be successfully infused to equilibrium distributions in
rodent and primate brain within acceptable time
frames (60 min). ([11C]NMPyB also differs in phar-
macokinetics and sensitivity to endogenous acetylcho-
line as compared to recently developed radioiodinated
ligands for SPECT such as [123I]IQNP, which requires
long imaging times (48 h) to reach peak equilibrium
and which have not been shown to be sensitive to
endogenous neurotransmitter (Nobuhara et al., 2001).
According to the occupancy model for radiotracer-
endogenous ligand competition, increases or decreases
in ACh levels should lead to lower or higher DVR,
respectively. The decreases observed here in the rat
brain following AChE inhibition show that 2 follows
the classic occupancy model radioligand behavior, sim-
ilar to that reported for the structurally related N-ethyl
(3-EtPB) and N-propyl piperidinyl benzilates (3-PPB)
(Nishiyama et al., 2001). The decreases in radioligand
binding observed in our study (9–10%) and others (12–
18%; Nishiyama et al., 2001) are modest when com-
pared to the orders of magnitude changes in ACh con-
centrations induced by such AChE inhibitors as
phenserine or Aricept. However, relatively small
changes in receptor-based radiotracer occupancy in re-
sponse to extremely high alterations in endogenous
neurotransmitter is often the norm in these types of
experiments (Laruelle, 2000).
The relationships between in vitro affinity of mAChR
ligands, specificity of in vivo binding, and sensitivity to
endogenous acetylcholine remain ambiguous, although
the available data does suggest that lower-affinity com-
pounds are more sensitive. Strict comparisons of the
available literature data are made more difficult, as in
vitro binding affinities for the identical compounds can
vary by more than 20-fold in data from different labo-
ratories, the in vivo studies have been done in both
rodents and primates, and data analyses done using
different pharmacokinetic modeling approaches. The
greatest sensitivity appears to reside in the compounds
with the poorer in vitro binding affinities, such as the
propyl derivative 3-PPB and the fluoroethyl derivative
4-FEPB. In our prior in vitro assays of these two com-
pounds we found very similar Ki values (3-PPB, 1.88
nM; 4-FEPB, 1.83 nM) for inhibition of [3H]scopol-
amine binding; in contrast, Nishiyama et al. (2001)
report a Ki value of 47 nM for 3-PPB, using [
3H]quini-
clidinyl benzilate as radioligand in the in vitro assay.
The reasons for this discrepancy are not evident. No
sensitivity to acetylcholinesterase pretreatment was
previously shown (Nishiyama et al., 2001) for the very
high-affinity N-methyl compound 4-NMPB (Ki  0.07
nM; Skaddan et al., 2000). The compounds with inter-
mediate affinities such as the pyrrolidinyl derivative
4-NMPyB (Ki 0.72 nM), studied here, and the N-ethyl
derivative 3-EtPB (Ki 12.9 nM by Nishiyama et al.
[2001] and Ki 1.46 nM by Skaddan et al. [2000]) show
small sensitivities to changes of endogenous acetylcho-
line. Thus, as in other receptor systems (Laruelle,
2001), it remains difficult to predict the sensitivity of a
radiotracer to changes of endogenous competitor neu-
rotransmitter based simply on the equilibrium in vitro
binding affinity. Our preliminary attempts to alter the
in vivo binding of [11C]NMPyB in the primate brain,
using administration of acetylcholinesterase inhibi-
tors, have proven unsuccessful. It is not clear if this
was due to the affinity of our new radioligand
[11C]NMPyB or a result of insufficient increases of the
endogenous acetylcholine levels in the primate brain;
further studies are needed. Even more perplexing are
the opposite behaviors of closely related compounds
such as [18F]FEPB and [11C]EPB (and [11C]NMPyB),
although it can be hypothesized that the fluoroethyl
substituent induces a significant physiochemical
change in the ligand: addition of a fluoroethyl group
has been shown to decrease the pKa of pyrrolidyl
amines in dopaminergic benzamides by as much as
100-fold (Schmidt et al., 1994). How such a change
results in differential binding of ligands, perhaps to
internalized vs. externalized muscarinic receptors, re-
mains to be determined.
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